Study design (if review, criteria of inclusion for studies)
Interventional - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
Participants
Cystic Fibrosis (CF) - 18 Years and older (Adult, Older Adult)
Interventions
Drug: Galicaftor|Drug: Placebo|Drug: Navocaftor|Drug: ABBV-119
Outcome measures
Absolute Change From Baseline in ppFEV1|Absolute Change From Baseline in Sweat Chloride (SwCl)|Absolute Change From Baseline in Forced Vital Capacity [FVC]|Absolute Change From Baseline in Forced Expiratory Flow at Mid-Lung Capacity [FEF25-75]|Relative Changes From Baseline in ppFEV1|Relative Changes From Baseline in FVC|Relative Changes From Baseline in FEF25-75|Absolute Change in CF Questionnaire-Revised (CFQ-R) Respiratory Domain Score From Baseline